Today: 10 June 2026
LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury
10 June 2026
3 mins read

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

PARIS, June 10, 2026, 10:46 CEST

  • LVMH hovered near €490 in Paris Wednesday morning, drifting lower after four sessions of gains that had pushed the stock up to €492.30 on Tuesday.
  • RBC kept its Buy rating and €600 target on LVMH. The focus stays on whether LVMH shares, which have been hit hard, can find their footing after a rough start to 2026.
  • The focus now is on July’s first-half numbers, with markets watching for a pickup in Fashion & Leather Goods and signs the Middle East drag is lessening.

LVMH Moët Hennessy Louis Vuitton SE shares traded lower in Paris early Wednesday, easing after their recent comeback that had pushed the stock close to €500. Investors took in a new Buy reiteration from RBC while also looking at the group’s projected 2026 losses. Shares listed on Euronext Paris were at €489.90, down 0.49%, according to MarketScreener. LVMH is still up 6.3% over the past five sessions but off about 24% since Jan. 1.

LVMH didn’t issue a new operating update—just a shift in tone from the day before. The stock had finished Tuesday at €492.30, a 2.04% jump, after rising 0.71% Monday, 1.04% Friday, and 2.88% last Thursday. But by Wednesday morning, the five-day chart started to show LVMH giving back some ground.

RBC is sticking with its bullish stance on LVMH. MarketScreener, quoting dpa-AFX Analyser, said Wednesday that RBC kept a Buy on the stock, with a €600 target price. That target is where analysts think shares may go, not a promise.

LVMH doesn’t carry the same runaway-growth price tag it used to. MarketScreener’s Euronext Paris page pegged its market cap at roughly €244 billion. The stock is still down double digits for the year, bounce aside.

In the past 24 hours, LVMH put out a regulatory note. The company said on June 9 it filed details of share transactions from June 1 to June 5 with the AMF, France’s markets watchdog, and posted them in its regulated info section. This was a standard compliance document, not related to trading.

The April first-quarter report is where things stand. LVMH posted Q1 revenue of €19.1 billion, down 6% on a reported basis, but up 1% organically. Organic growth means results exclude currency effects and consolidation changes. LVMH said exchange rates alone cut reported growth by 7 percentage points.

Fashion & Leather Goods is in the spotlight. That division, which includes Louis Vuitton and Dior, brought in €9.25 billion in Q1 sales, the biggest among business groups. But revenue slid 2% organically and dropped 9% reported. Pricing and brand momentum are critical for the stock’s valuation, so this figure carries outsized weight.

There were some offsets. Watches & Jewelry was up 7% organically, Selective Retailing added 4%, and Wines & Spirits gained 5%, getting a lift from champagne and a timing boost for cognac around Chinese New Year. Still, those moves haven’t put to rest worry that the core fashion business isn’t yet showing clean growth.

Middle East tensions still weigh on sentiment, making it tough for the market to trust the rebound. LVMH said the conflict hit March sales, dragging quarterly group organic growth down by around 1 percentage point after a good start to the year. Europe and Japan managed solid local demand, LVMH said, which helped offset weaker tourist spending.

The issue extends past LVMH. In April, Reuters reported shares of Hermès dropped as much as 14% and Kering slid more than 9% on signs of weaker demand out of the Middle East and fewer tourists. The moves shook investors—big European luxury names took a hit.

Analysts aren’t outright bearish, but the mood has cooled. According to MarketScreener’s consensus page, 27 analysts have a mean Outperform call and set a €590.08 average target price, with the lowest target at €456. The range highlights the divide: some expect LVMH’s 2026 stumble to pass, others see a more stubborn luxury slowdown.

There’s a risk Wednesday’s drop in the shares is more than just noise. If Gulf shopping hubs keep underperforming, Middle Eastern travel to Europe stays down, or euro strength keeps hurting the numbers, LVMH’s slim 1% organic growth in Q1 could disappear. A miss in Fashion & Leather Goods would also make those higher target prices less credible.

LVMH’s next big date is in July, when the group will report 2026 first-half results according to its financial calendar. The focus: can the Middle East headwind subside, and will Louis Vuitton, Dior, and Fashion & Leather Goods get growth back after holding steady?

Stock Market Today

  • Nasdaq and S&P 500 Futures Slip Ahead of U.S. CPI Data and Oracle Earnings
    June 10, 2026, 5:08 AM EDT. Nasdaq futures dropped 0.6% and S&P 500 futures fell 0.4% early Wednesday amid fresh geopolitical tensions following U.S. strikes on Iran. Investors await the May Consumer Price Index (CPI) report, which could hit three-year highs due to persistent food and energy inflation. Oracle's Q4 earnings, expected after market close, may reveal if the company's cloud growth supports its AI investments. Semiconductor stocks show mixed signals: Taiwan Semiconductor's sales rose 30% year-over-year, yet shares declined 2% on regulatory concerns. Super Micro Computer shares plunged 10% after announcing a $7 billion financing deal to support AI infrastructure backlogs. Coreweave faced additional pressure following insider share sales. SpaceX's IPO demand surged to $250 billion, nearly quadruple oversubscribed. Retail sentiment on ETFs tracking major indexes turned cautious amid market rotation away from AI and semiconductor stocks.

Latest articles

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

10 June 2026
LVMH shares slipped 0.49% to €489.90 in Paris after a four-day rebound, as investors weighed RBC’s reiterated Buy rating with a €600 target against ongoing 2026 losses and a 24% year-to-date drop; all eyes now turn to July’s first-half results for signs of recovery in Fashion & Leather Goods and any relief from Middle East weakness.
Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

10 June 2026
Tencent shares jumped 3.22% to HK$467.80 after the company priced a larger-than-expected US$4.66 billion dual-currency bond deal, drawing over US$17 billion in orders and allowing tighter pricing, as investors weighed Tencent’s ability to fund rising AI investments while maintaining strong cash flow and ongoing share buybacks.
PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

10 June 2026
Paranovus Entertainment Technology shares jumped 19.6% premarket after filing plans for an at-the-market share sale of up to $194.99 million—an unusually large amount compared to its $1.07 million market value—raising dilution risks as the company can sell shares at prevailing prices with no minimums, while recent trading has been highly volatile and underlying operations remain limited.
Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact
Previous Story

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Go toTop